BLOCKADE OF RIPK3 MODIFIES RENAL FIBROGENESIS THROUGH INHIBITION OF NF ΚB

Y SHI1,  C HUANG1, X CHEN1, C POLLOCK1
1Kolling Institute, Royal North Shore Hospital, St Leonards, Australia

Aim: To define the role of receptor-interacting protein kinase 3 (RIPK3) in alleviating renal fibrogenesis.
Background: Current therapies for renal fibrosis are largely ineffective. Therefore, identification of novel therapeutic targets is essential. RIPK3 is identified as a crucial regulator of Interleukin-1 (IL-1) secretion via the necroptotic pathway and the nuclear factor NF κB pathway, which have been well recognised to be involved in renal fibrogenesis by regulating TGF-β. To date, the function of RIPK3 in renal fibrosis remains unclear.
Methods: C57BL/6 wild-type mice and C57BL/6 RIPK3 gene knock out (RIPK3-/-) mice were used in the study. Renal fibrosis was induced with folic acid (250 mg/kg) and animals were killed at 28th day after folic acid injection. Dabrafenib (2.5 μg/hr) was used as a pharmacological inhibitor of RIPK3.
Results: FA nephropathy led to a significant renal injury within in the kidney cortex characterized by tubular dilation, tubule atrophy, cast formation and inflammatory cell infiltration (p<0.0001). These pathological changes were accompanied by an elevation in expression of pro‐fibrotic markers (collagen I, p<0.05; collagen III, p<0.05; TGF-β, p<0.0001), myofibroblast activation (α-SMA, p<0.0001) and inflammatory response (MCP-1, p<0.0001; F4/80, p<0.0001, phosphorylated p65, p<0.01). Genetic ablation of RIPK3 or RIPK3 inhibition abrogated all markers of renal injury (all p<0.05), fibrotic responses (all p<0.05) and inflammation (all p<0.05). However, IL-1 production was not modified.
Conclusions: These results suggest that RIPK3 may be a potential novel target in renal fibrosis. However, the beneficial effects are likely to be mediated through inhibition of NFKB and independent of the necroptotic pathway.


Biography:
Ying Shi is is a PhD candidate in Medicine at the University of Sydney under the supervision of Prof. Carol Pollock. Her research focuses on identifying novel therapeutic target for renal fibrosis.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd